Enzo Biochem has 33.78
M in debt with debt to equity (D/E) ratio of 0.54, which is OK given its current industry classification. The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Enzo Biochem has an asset utilization ratio of 69.24 percent. This suggests that the company is making $0.69 for each dollar of assets. An increasing asset utilization means that Enzo Biochem is more efficient with each dollar of assets it utilizes for everyday operations.
We determine the current worth of Enzo Biochem using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Enzo Biochem based exclusively on its
fundamental and basic
technical indicators. By analyzing Enzo Biochem's
financials, quarterly and monthly indicators, and related drivers such as
dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of
Enzo Biochem's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Enzo Biochem. We calculate exposure to Enzo Biochem's
market risk, different
technical and
fundamental indicators, relevant financial multiples and ratios, and then
comparing them to Enzo Biochem's related companies.
Watch out for price decline
Please consider monitoring Enzo Biochem on a daily basis if you are holding a position in it. Enzo Biochem is trading at a penny-stock level, and the possibility of delisting is much higher compared to other stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion.
Most exchanges require public instruments, such as Enzo Biochem stock to be traded above the $1 level to remain listed. If Enzo Biochem stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
Enzo Biochem Investment Alerts
Enzo investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring Enzo Biochem performance across your portfolios.Please check all
investment alerts for Enzo
Enzo Biochem Valuation Ratios as Compared to Competition
Our valuation model uses many indicators to compare Enzo value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Enzo Biochem competition to find
correlations between indicators driving the intrinsic value of Enzo.
Enzo Biochem Gross Profit
Enzo Biochem Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Enzo Biochem previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Enzo Biochem Gross Profit growth over the last 10 years. Please check Enzo Biochem's
gross profit and other
fundamental indicators for more details.
Breaking it down a bit more
The current indifference towards the small price fluctuations of Enzo Biochem could raise concerns from investors as the firm it trading at a share price of
2.57 on slow start in volume. The company executives did not add any value to Enzo Biochem investors in
September. However, most investors can still diversify their portfolios with Enzo Biochem to hedge their inherited risk against high-volatility market scenarios. The stock standard deviation of daily returns for 30 days investing horizon is currently 3.25. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from Enzo Biochem partners.
Margins Breakdown
Enzo Biochem profit margins show the degree to which it makes money. Margin indicators are used not only by investors but also by creditors or Enzo Biochem itself as indicators of financial health and management effectiveness. Please look more closely at the different varieties of Enzo Biochem profit margins.
| Operating Margin | 2.07 |
| EBITDA Margin | 0.0683 |
| Gross Margin | 0.32 |
| Profit Margin | 0.0384 |
Enzo Biochem Net Income Per Employee is increasing over the last 8 years. The current value of Enzo Biochem Net Income Per Employee is 4,834. Moreover, Enzo Biochem Earnings Before Interest Taxes and Depreciation Amortization EBITDA is fairly stable at the moment.
Our take on today Enzo Biochem rise
Current Information Ratio is up to -0.09. Price may slide again. Enzo Biochem exhibits very low volatility with skewness of 0.15 and kurtosis of 0.12. However, we advise investors to further study Enzo Biochem technical indicators to make sure all market info is available and is reliable.
The Bottom Line
While some other firms within the diagnostics & research industry are still a little expensive, even after the recent corrections, Enzo Biochem may offer a potential longer-term growth to investors. In closing, as of the 13th of October 2020, our final 30 days Buy-Hold-Sell recommendation on the company is
Strong Hold. We believe Enzo Biochem is currently
undervalued with
below average chance of financial distress for the next two years.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Rifka Kats is a Member of Macroaxis Editorial Board. Rifka writes about retail product and service companies from the perspective of a regular consumer and sophisticated investor at the same time. She is passionate about corporate ethics and equality in the workforce.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Rifka Kats do not own shares of Enzo Biochem. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
